In silico discovery of RIOK3 inhibitors against pancreatic ductal adenocarcinoma using homology modelling, molecular docking, molecular dynamics simulations, ADMET prediction, and MTT assay
RIOK3 is identified as a promising therapeutic target for PDAC, with Venetoclax, Conivaptan, Drospirenone, and Irinotecan as repurposable candidates for further research.